Studi Penggunaan Glukokortikoid Pada Pasien Penyakit Paru Obstruktif Kronik Di RSUD R.T. Notopuro Sidoarjo

study on the Use of Glucocorticoids in Patients with Chronic Obstructive Pulmonary Disease At R.T. notopuro, Sidoarjo Hospital

Authors

  • Audin Nur Affifah Febriyanti Universitas PGRI Adi Buana Author
  • Ira Purbosari Universitas PGRI Adi Buana Author
  • Fajar Jamaluddin Sandhori Universitas PGRI Adi Buana Author

DOI:

https://doi.org/10.30872/jsk.v6i2.828

Keywords:

DRP, Glukokortikoid, ICS, Oral, PPOK

Abstract

Penyakit Paru Obstruktif Kronik (PPOK) ialah penyakit saluran napas kronis yang ditandai dengan terbatasnya aliran udara secara progresif serta adanya peradangan jangka panjang di saluran napas. Penelitian ini bertujuan untuk mengevaluasi pola penggunaan glukokortikoid pada pasien PPOK di RSUD R.T. Notopuro Sidoarjo, meliputi jenis obat, dosis, rute pemberian, frekuensi, lama terapi, serta mengidentifikasi adanya Drug Related Problems (DRP) berupa interaksi obat dan analisa terapi tambahan terhadap efek samping penggunan glukokortikoid. Penelitian ini bersifat non-eksperimental dan dilaksanakan secara observasional dengan metode retrospektif terhadap data rekam medis pasien PPOK rawat inap periode Januari 2023–Desember 2024. Dari 90 sampel pasien yang diteliti, didapatkan 75% menerima terapi glukokortikoid tunggal, dan 25% menerima terapi kombinasi. Dengan rute pemberian metilprednisolon sistemik (98,9%), baik secara injeksi (125 mg) maupun oral (4–8 mg). Inhalasi budesonid (20,8%) pasien dan flutikason (4,2%) pasien. Frekuensi pemberian terbanyak adalah tiga kali sehari dan durasi terapi kurang dari lima hari. DRP yang ditemukan meliputi interaksi mayor (metilprednisolon + levofloxacin), moderate (metilprednisolon + vitamin D), dan minor (metilprednisolon + salbutamol).

References

[1] A. Rahayu, I. Purbosari, I. A. K. Pramushinta, and I. D. Framono, “Sosialisasi Pemanfaatan Jus Semangka untuk Meningkatkan Kadar Oksigen dan Daya Tahan Tubuh,” J. Pengabdi. Masy. Bangsa, vol. 1, no. 5, pp. 415–419, 2023

[2] Motruk, D. (2018) ‘Global Initiative for Chronic Obstructive Lung Disease’, Medicine of Ukraine, 0(1(217)), pp. 8–10. Available at: https://doi.org/10.37987/1997-9894.2018.1(217).195220.

[3] Permatasari, C.Y. (2016) Studi Penggunaan Kortikosteroid Pada Pasien Penyakit Paru Obstruktif Kronis (PPOK) Di RSUD. Soetomo Surabaya, ADLN- Perpustaka Universitas Airlangga

[4] PDPI. (2023). Pedoman Diagnosis Dan Penatalaksanaan PPOK Di Indonesia. In A. Budhi, B. Arief, & W. H. Wiwien (Eds.), Penyakit Paru Obstruktif Kronik (pp. 1–171). Perhimpunan Dokter Paru Indonesia. https://bukupdpi.klikpdpi.com/buku-ppok-2023/

[5] Barnes, P.J. (2017) ‘GOLD 2017: A New Report’, Chest, 151(2), pp. 245–246.Available at: https://doi.org/10.1016/j.chest.2016.11.042.

[6] Rinawan, A. (2019) ‘Laporan Studi Kasus Pada Pasien Gangguan Pernapasan Dengan Diagnosa Penyakit Paru Obstruktif Kronik Di Ruang ICU RSUD Pandan Arang Boyolali.’, pp. 1–23.

[7] GOLD (2019) ‘Chronic Obstructive Pulmonary Disease 2019 Report Global Initiative for Chronic Obstructive Lung Disease (GOLD)’, Gold, pp. 1–139.

[8] Papadopoulou, E. et al. (2024) ‘Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis’, European Respiratory Review, 33(171). Available at: https://doi.org/10.1183/16000617.0151-2023

[9] Frenkel, A. et al. (2019) ‘The association of glucocorticosteroid treatment with WBC count in patients with COPD exacerbation’, Journal of Clinical Medicine, 8(10). Available at: https://doi.org/10.3390/jcm8101697.

[10] Allfazmy, P., Warlem, N., & Amran, R. (2022). Faktor Risiko Penyakit Paru Obstruksi Kronik (PPOK) di Semen Padang Hospital (SPH). Scientific Journal, 1(1), 19–23. https://doi.org/10.56260/sciena.v1i1.18

[11] Ramadhani, S., Purwono, J., & Utami, I. T. (2022). Penerapan Pursed Lip Breathing Terhadap Penurunan Sesak Napas Pada Pasien Penyakit Paru Obstruksi Kronik (PPOK) Di Ruang Paru RSUD Jend. Ahmad Yani Kota Metro. Jurnal Cendikia Muda, 2(2), 276–284.

[12] Mackey, E., & Moeser, A. J. (2022). Sex Differences in Mast Cell–Associated Disorders: A Life Span Perspective. Cold Spring Harbor Perspectives in Biology, 14(10), 1–14. https://doi.org/10.1101/cshperspect.a039172

[13] Alexander E, Butler CD, Darr A, Jenkins MT, Long R., Shipman C., et al. Statement on Telepharmacy. Vol. 74. 2017

[14] Sheetu Singh, Neeraj Sharma, Udaiveer Singh, Tejraj Singh, Mangal, D. K., & Singh, V. (2018). Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID‑19? Lung India, 35(1), 41–46. https://doi.org/10.4103/lungindia.lungindia

[15] Fitrian, V. F., Mubaraq, S. El, & Musdalifah. (2023). LAPORAN KASUS : PPOK EKSASERBASI AKUT DAN BRONKOPNEUMONIA DENGAN DEXTROCARDIA Case Report: Acute Exacerbation Of COPD And Bronchopneumonia With Dextrocardia. 539–554.

[16] Kurniyanti, N., Rahmawati, Yusuf Kidingallo, Wiriansya, E. P., & Raden Selma. (2023). Karakteristik Pasien Penyakit Paru Obstruktif Kronik di Rumah Sakit Ibnu Sina Makassar. Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran, 3(5), 350–356. https://doi.org/10.33096/fmj.v3i5.230

[17] Indreswari, Y. S., Ruende, C. M., & Pitoyo, C. W. (2015). Faktor-Faktor yang berhubungan dengan Ekserbasi pada Pasien Penyakit Paru Obstruktif Kronik di Rumah Sakit Cipto Mangunkusumo. Faktor-Faktor Yang Berhubungan Dengan Ekserbasi Pada Pasien Penyakit Paru Obstruktif Kronik Di Rumah Sakit Cipto Mangunkusumo, 1(4), 160–165

[18] Ardestani, M. E., Kalantary, E., Samaiy, V., & Taherian, K. (2019). Methylprednisolone vs dexamethason in management of COPD exacerbation; a randomized clinical trial. Archives of Academic Emergency Medicine, 7(1), 1–6.

[19] Tashkin, D. P., & Strange, C. (2018). Inhaled corticosteroids for chronic obstructive pulmonary disease: What is their role in therapy? International Journal of COPD, 13, 2587–2601. https://doi.org/10.2147/COPD.S172240

[20] Nedzlek, C., Blanchett, J., Illg, Z., Digiacinto, G., Cunningham, K., Wisniewski, S. J., & Tuttle, J. (2024). Corticosteroid Prescribing Patterns in the Emergency Department for Acute Chronic Obstructive Pulmonary Disease Exacerbations : A Retrospective Analysis Following an Educational Intervention. 9(3), 51–57. https://doi.org/10.51894/001c.124542

[21] Jae, W., Dj, T., Cj, W., Pg, G., Eh, W., Jae, W., Dj, T., Cj, W., Pg, G., & Eh, W. (2015). obstructive pulmonary disease ( Review ). https://doi.org/10.1002/14651858.CD001288.pub4.www.cochranelibrary.com

[22] Jatmiko, R., & Oktianti, D. (2023). Evaluasi Pengobatan pada Pasien Penyakit Paru Obstruksi. 5(2), 331–339.

[23] Zhao, Z., Xiong, R., Cui, Y., He, X., Meng, W., Wu, J., Wang, J., Zhao, R., Zeng, H., & Chen, Y. (2025). Efficacy of Nebulized Budesonid and Systemic Corticosteroids During Hospitalization on All-Cause Mortality in AECOPD Patients: A Real-World Study. Lung, 203(1), 30. https://doi.org/10.1007/s00408-024-00784

[24] Terry, P. D., & Dhand, R. (2020). Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation. Pulmonary Therapy, 6(2), 177–192. https://doi.org/10.1007/s41030-020-00120-x

[25] Sivapalan, P., Rutishauser, J., Ulrik, C. S., Leuppi, J. D., Pedersen, L., Mueller, B., Eklöf, J., Biering-Sørensen, T., Gottlieb, V., Armbruster, K., Janner, J., Moberg, M., Lapperre, T. S., Nielsen, T. L., Browatzki, A., Mathioudakis, A., Vestbo, J., Schüetz, P., & Jensen, J. U. (2021). Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. Respiratory Research, 22(1), 1–9. https://doi.org/10.1186/s12931-021-01745-5

[26] Ramakrishnan, S., Jeffers, H., Langford-Wiley, B., Davies, J., Thulborn, S. J., Mahdi, M., A’Court, C., Binnian, I., Bright, S., Cartwright, S., Glover, V., Law, A., Fox, R., Jones, A., Davies, C., Copping, D., Russell, R. E., & Bafadhel, M. (2024). Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. The Lancet Respiratory Medicine, 12(1), 67–77. https://doi.org/10.1016/S2213-2600(23)00298-9

[27] Agustí, A. et al. (2023) ‘Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary’, American Journal of Respiratory and Critical Care Medicine, 207(7), pp. 819–837. Available at: https://doi.org/10.1164/rccm.202301-0106PP.

[28] Hanutami, B., & Dandan, K. L. (2019). Identifikasi potensi interaksi antar obat pada resep umum di Apotek Kimia Farma 58 Kota Bandung bulan April 2019. Farmaka, 17(April), 57–64.

[29] Drug.com. (2025). Drug Interaction Checker. https://www.drugs.com/drug_interactions.html

[30] Yasir, M., Goyal, A., & Sonthalia, S. (2023). Corticosteroid Adverse Effects. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK531462/

[31] Melani, A. S., Croce, S., Fabbri, G., Messina, M., & Bargagli, E. (2024). Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules, 14(2). https://doi.org/10.3390/biom14020195

[32] Suh, S., & Park, M. K. (2017). Glucocorticoid-induced diabetes mellitus: An important but overlooked problem. Endocrinology and Metabolism, 32(2), 180–189. https://doi.org/10.3803/EnM.2017.32.2.180

[33] Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021). Management of diabetes and hyperglycaemia in the hospital. The Lancet Diabetes and Endocrinology, 9(3), 174–188. https://doi.org/10.1016/S2213-8587(20)30381-8

[34] Putri Egiestine, D. et al. (2023) ‘Gambaran Kepatuhan Penggunaan Inhaler Lama Dan Quality Of Life Pada Pasien PPOK Di Kabupaten Pringsewu Provinsi Lampung Abtract: Description of Adherence of The Use Lama Inhaler and Quality of life in COPD Patients in Pringsewu District Lampung Province’, Jurnal Ilmu Kedokteran dan Kesehatan, 10(5), pp. 2549–4864. Available at: http://ejurnalmalahayati.ac.id/index.php/kesehatan.

Downloads

Published

2025-07-31

Issue

Vol. 6 No. 2 (2025)

Section

Articles

License

Copyright (c) 2025 Jurnal Sains dan Kesehatan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
A. N. A. . Febriyanti, I. Purbosari, and F. J. Sandhori, “Studi Penggunaan Glukokortikoid Pada Pasien Penyakit Paru Obstruktif Kronik Di RSUD R.T. Notopuro Sidoarjo: study on the Use of Glucocorticoids in Patients with Chronic Obstructive Pulmonary Disease At R.T. notopuro, Sidoarjo Hospital”, J. Sains. Kes, vol. 6, no. 2, pp. 116–127, Jul. 2025, doi: 10.30872/jsk.v6i2.828.

Most read articles by the same author(s)

Similar Articles

11-20 of 26

You may also start an advanced similarity search for this article.